메뉴 건너뛰기




Volumn 8, Issue 11, 2011, Pages 1481-1500

Drug delivery strategies for poorly water-soluble drugs: The industrial perspective

Author keywords

Biorelevant solubilization; Drug delivery; Liposomes solubilization; Nano suspension; Poorly water soluble drug; Poorly water soluble drug dissolution; Solubilization

Indexed keywords

ALCOHOL; APREPITANT; ASCORBIC ACID PLUS VITAMIN B COMPLEX; BUSULFAN; CYCLODEXTRIN; CYCLOSPORIN A; FENOFIBRATE; FOSAPREPITANT; FUROSEMIDE; ITRACONAZOLE; LEUPRORELIN; LIPOSOME; LOPINAVIR PLUS RITONAVIR; MEGESTROL ACETATE; MITOMYCIN; PACLITAXEL; PHYTOMENADIONE; PROPYLENE GLYCOL; RAPAMYCIN; ROSUVASTATIN; TACROLIMUS; TECHNETIUM 99M; VORICONAZOLE;

EID: 80054794155     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.614228     Document Type: Review
Times cited : (130)

References (123)
  • 1
    • 24644453083 scopus 로고    scopus 로고
    • Transfer of lipophilic drugs between liposomal membranes and biological interfaces: Consequences for drug delivery
    • DOI 10.1016/j.ejps.2005.05.012, PII S0928098705001922
    • Fahr A, van Hoogevest P, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-65 (Pubitemid 41278632)
    • (2005) European Journal of Pharmaceutical Sciences , vol.26 , Issue.3-4 , pp. 251-265
    • Fahr, A.1    Hoogevest, P.V.2    May, S.3    Bergstrand, N.4    Leigh, M.L.S.5
  • 2
    • 54349108703 scopus 로고    scopus 로고
    • Commissioner of Food and Drugs Rockville MD 20857
    • Commissioner of Food and Drugs. Nanotechnology Task Force Report, FDA Rockville MD 20857, 2007
    • (2007) Nanotechnology Task Force Report, FDA
  • 5
    • 34548484667 scopus 로고    scopus 로고
    • Nano-based drugs and medical devices: FDA's track record
    • Strickland CH. Nano-based drug and medical devices: FDA track record. Nanotechnol Law Bus 2007;4:179-88 (Pubitemid 47510236)
    • (2007) Nanotechnology Law and Business , vol.4 , Issue.2 , pp. 179-188
    • Strickland, C.H.1
  • 8
    • 34547864243 scopus 로고    scopus 로고
    • Drug delivery strategies for poorly water-soluble drugs
    • DOI 10.1517/17425247.4.4.403
    • Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;4:403-16 (Pubitemid 47249138)
    • (2007) Expert Opinion on Drug Delivery , vol.4 , Issue.4 , pp. 403-416
    • Fahr, A.1    Liu, X.2
  • 9
    • 1842689072 scopus 로고    scopus 로고
    • Pharmaceutical evaluation of early development candidates "the 100 mg-approach"
    • DOI 10.1016/j.ijpharm.2004.01.034, PII S0378517304000699
    • Balbach S, Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm 2004;275:1-12 (Pubitemid 38481515)
    • (2004) International Journal of Pharmaceutics , vol.275 , Issue.1-2 , pp. 1-12
    • Balbach, S.1    Korn, C.2
  • 10
    • 77956609919 scopus 로고    scopus 로고
    • Development and application of a high throughput screening for oral administration in drug discovery
    • Gopinathan S, Noraldeen A, Wilson AGE. Development and application of a high throughput screening for oral administration in drug discovery. Future Med Chem 2010;2:1392-8
    • (2010) Future Med Chem , vol.2 , pp. 1392-8
    • Gopinathan, S.1    Noraldeen, A.2    Wilson, A.G.E.3
  • 11
    • 77249111754 scopus 로고    scopus 로고
    • Porous carriers for controlled/modulated drug delivery
    • Ahuja G, Pathak K. Porous carriers for controlled/modulated drug delivery. Indian J Pharm Sci 2009;71:599-607
    • (2009) Indian J Pharm Sci , vol.71 , pp. 599-607
    • Ahuja, G.1    Pathak, K.2
  • 13
    • 51249101525 scopus 로고    scopus 로고
    • Nanocrystalline pharmaceutical patent litigation the first case
    • Prendergast WF, Schafer HN. Nanocrystalline pharmaceutical patent litigation: the first case. Nanotechnol Law Bus 2008;5:157-61
    • (2008) Nanotechnol Law Bus , vol.5 , pp. 157-61
    • Prendergast, W.F.1    Schafer, H.N.2
  • 15
    • 0022404616 scopus 로고
    • Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog
    • DOI 10.1007/BF01983649
    • Masini E, Planchenault J, Pezziardi F, et al. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-7 (Pubitemid 16220968)
    • (1985) Agents and Actions , vol.16 , Issue.6 , pp. 470-477
    • Masini, E.1    Planchenault, J.2    Pezziardi, F.3
  • 16
    • 0025910768 scopus 로고
    • The hemodynamic effects of Cremophor-EL
    • Bowers VD, Locker S, Ames S, et al. The hemodynamic effects of Cremophor-EL. Transplantation 1991;51:847-50
    • (1991) Transplantation , vol.51 , pp. 847-50
    • Bowers, V.D.1    Locker, S.2    Ames, S.3
  • 17
    • 0023948933 scopus 로고
    • Study of histamine release induced by acute administration of antitumor agents in dogs
    • Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988;21:246-50
    • (1988) Cancer Chemother Pharmacol , vol.21 , pp. 246-50
    • Eschalier, A.1    Lavarenne, J.2    Burtin, C.3
  • 19
    • 0022615494 scopus 로고
    • Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El® (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions?
    • Ennis M, Lorenz W, Gerland W. Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions? Agents Actions 1986;18:235-8 (Pubitemid 16113264)
    • (1986) Agents and Actions , vol.18 , Issue.1-2 , pp. 235-238
    • Ennis, M.1    Lorenz, W.2    Gerland, W.3
  • 20
    • 0021955562 scopus 로고
    • Comparison of the histamine-releasing activity of cremophor E1® and some of its derivatives in two experimental models: The in vivo anaesthetized dog and in vitro rat peritoneal mast cells
    • DOI 10.1007/BF01983156
    • Ennis M, Lorenz W, Kapp B, et al. Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 1985;16:265-8 (Pubitemid 15116711)
    • (1985) Agents and Actions , vol.16 , Issue.3-4 , pp. 265-268
    • Ennis, M.1    Lorenz, W.2    Kapp, B.3
  • 21
    • 0017346930 scopus 로고
    • Histamine release in dogs by Cremophor E1 and its derivatives: Oxethylated oleic acid is the most effective constituent
    • Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7 (Pubitemid 8070781)
    • (1977) Agents and Actions , vol.7 , Issue.1 , pp. 63-67
    • Lorenz, W.1    Reimann, H.J.2    Schmal, A.3
  • 22
    • 0019997303 scopus 로고
    • Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in cremophor E1 and development of a compound with reduced toxicity
    • DOI 10.1007/BF01965109
    • Lorenz W, Schmal A, Schult H, et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents Actions 1982;12:64-80 (Pubitemid 12076385)
    • (1982) Agents and Actions , vol.12 , Issue.1-2 , pp. 64-80
    • Lorenz, W.1    Schmal, A.2    Schult, H.3
  • 23
    • 80054804979 scopus 로고    scopus 로고
    • Applications of Solutol HS 15
    • Thaysen G. Applications of Solutol HS 15 In: ExAct B; 1999. p. 7
    • (1999) ExAct B , pp. 7
    • Thaysen, G.1
  • 25
    • 1242337285 scopus 로고    scopus 로고
    • Solubilizing Excipients in Oral and Injectable Formulations
    • DOI 10.1023/B:PHAM.0000016235.32639.23
    • Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30 (Pubitemid 38221966)
    • (2004) Pharmaceutical Research , vol.21 , Issue.2 , pp. 201-230
    • Strickley, R.G.1
  • 26
    • 33748504537 scopus 로고    scopus 로고
    • Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery?
    • DOI 10.1080/08982100600848702, PII M86505185166M711
    • Fahr A, van Hoogevest P, Kuntsche J, et al. Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J Liposome Res 2006;16:281-301 (Pubitemid 44359001)
    • (2006) Journal of Liposome Research , vol.16 , Issue.3 , pp. 281-301
    • Fahr, A.1    Van Hoogevest, P.2    Kuntsche, J.3    Leigh, M.L.S.4
  • 27
    • 39149095938 scopus 로고    scopus 로고
    • Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation
    • Dai WG, Pollock-Dove C, Dong LC, et al. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation. Adv Drug Deliv Rev 2008;60:657-72
    • (2008) Adv Drug Deliv Rev , vol.60 , pp. 657-72
    • Dai, W.G.1    Pollock-Dove, C.2    Dong, L.C.3
  • 28
    • 34047271049 scopus 로고    scopus 로고
    • Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material
    • DOI 10.1016/j.ijpharm.2006.11.034, PII S0378517306009768
    • Dai WG, Dong LC, Li S, et al. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int J Pharm 2007;336:1-11 (Pubitemid 46551550)
    • (2007) International Journal of Pharmaceutics , vol.336 , Issue.1 , pp. 1-11
    • Dai, W.-G.1    Dong, L.C.2    Li, S.3    Pollock-Dove, C.4    Chen, J.5    Mansky, P.6    Eichenbaum, G.7
  • 29
    • 34250746898 scopus 로고    scopus 로고
    • Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: Miniaturization and automation of solvent casting and dissolution testing
    • DOI 10.1002/jps.20799
    • Mansky P, Dai WG, Li S, et al. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J Pharm Sci 2007;96:1548-63 (Pubitemid 46953770)
    • (2007) Journal of Pharmaceutical Sciences , vol.96 , Issue.6 , pp. 1548-1563
    • Mansky, P.1    Dai, W.-G.2    Li, S.3    Pollock-Dove, C.4    Daehne, K.5    Dong, L.6    Eichenbaum, G.7
  • 30
    • 0037422391 scopus 로고    scopus 로고
    • An intravenous formulation decision tree for discovery compound formulation development
    • DOI 10.1016/S0378-5173(02)00704-4
    • Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm 2003;253:111-19 (Pubitemid 36197836)
    • (2003) International Journal of Pharmaceutics , vol.253 , Issue.1-2 , pp. 111-119
    • Lee, Y.-C.1    Zocharski, P.D.2    Samas, B.3
  • 31
    • 33846290338 scopus 로고    scopus 로고
    • Preclinical formulations for discovery and toxicology: Physicochemical challenges
    • DOI 10.1517/17425255.2.5.715
    • Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug MetabToxicol 2006;2:715-31 (Pubitemid 46118317)
    • (2006) Expert Opinion on Drug Metabolism and Toxicology , vol.2 , Issue.5 , pp. 715-731
    • Neervannan, S.1
  • 32
    • 34447646495 scopus 로고    scopus 로고
    • Developing early formulations: Practice and perspective
    • DOI 10.1016/j.ijpharm.2007.05.049, PII S0378517307004553
    • Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007;341:1-19 (Pubitemid 47088122)
    • (2007) International Journal of Pharmaceutics , vol.341 , Issue.1-2 , pp. 1-19
    • Li, P.1    Zhao, L.2
  • 33
    • 33847251189 scopus 로고    scopus 로고
    • Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration
    • Van Hoogevest P, Rogue V, Brumec M, et al. Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration. PDA J Pharm Sci Technol 2006;60:366-77
    • (2006) PDA J Pharm Sci Technol , vol.60 , pp. 366-77
    • Van Hoogevest, P.1    Rogue, V.2    Brumec, M.3
  • 34
    • 79952209766 scopus 로고    scopus 로고
    • Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs
    • Van Hoogevest P, Liu X, Fahr A, et al. Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. J Drug Deliv Sci Technol 2011;21:5-16
    • (2011) J Drug Deliv Sci Technol , vol.21 , pp. 5-16
    • Van Hoogevest, P.1    Liu, X.2    Fahr, A.3
  • 35
    • 77953404368 scopus 로고    scopus 로고
    • Nanosuspensions as a drug delivery system: A comprehensive review
    • Shah T, Patel D, Hirani J, et al. Nanosuspensions as a drug delivery system: a comprehensive review. Drug Delivery Technol 2007;7:42-53
    • (2007) Drug Delivery Technol , vol.7 , pp. 42-53
    • Shah, T.1    Patel, D.2    Hirani, J.3
  • 36
    • 79151476729 scopus 로고    scopus 로고
    • Universal wet-milling technique to prepare oral nanosuspensions focused on discovery and pre-clinical animal studies. Development of particle design method
    • Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspensions focused on discovery and pre-clinical animal studies. Development of particle design method. Int J Pharm 2011;405:218-27
    • (2011) Int J Pharm , vol.405 , pp. 218-27
    • Niwa, T.1    Miura, S.2    Danjo, K.3
  • 37
    • 0036234785 scopus 로고    scopus 로고
    • Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters
    • Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 2002;5:59-71 (Pubitemid 34453243)
    • (2002) Current Opinion in Drug Discovery and Development , vol.5 , Issue.1 , pp. 59-71
    • Bittner, B.1    Mountfield, R.J.2
  • 38
    • 0028948839 scopus 로고
    • A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
    • Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
    • (1995) Pharm Res , vol.12 , pp. 413-20
    • Amidon, G.L.1    Lennernas, H.2    Shah, V.P.3
  • 39
    • 78049495059 scopus 로고    scopus 로고
    • The developability classification system: Application of biopharmaceutics concepts to formulation development
    • Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 2010;99:4940-54
    • (2010) J Pharm Sci , vol.99 , pp. 4940-54
    • Butler, J.M.1    Dressman, J.B.2
  • 41
    • 0030793250 scopus 로고    scopus 로고
    • The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations
    • Corrigan OI. The biopharmaceutics drug classification and drugs administered in extended release (ER) formulations. Adv Exp Med Biol 1997;423:111-28 (Pubitemid 27347196)
    • (1997) Advances in Experimental Medicine and Biology , vol.423 , pp. 111-128
    • Corrigan, O.I.1
  • 42
    • 0031913402 scopus 로고    scopus 로고
    • Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
    • DOI 10.1023/A:1011984216775
    • Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22 (Pubitemid 28080861)
    • (1998) Pharmaceutical Research , vol.15 , Issue.1 , pp. 11-22
    • Dressman, J.B.1    Amidon, G.L.2    Reppas, C.3    Shah, V.P.4
  • 43
    • 0033452575 scopus 로고    scopus 로고
    • Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data
    • Nicolaides E, Galia E, Efthymiopoulos C, et al. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999;16:1876-82 (Pubitemid 30040705)
    • (1999) Pharmaceutical Research , vol.16 , Issue.12 , pp. 1876-1882
    • Nicolaides, E.1    Galia, E.2    Efthymiopoulos, C.3    Dressman, J.B.4    Reppas, C.5
  • 44
    • 0034080127 scopus 로고    scopus 로고
    • Dissolution testing as a prognostic tool for oral drug absorption: Dissolution behavior of glibenclamide
    • DOI 10.1023/A:1007529020774
    • Lobenberg R, Kramer J, Shah VP, et al. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res 2000;17:439-44 (Pubitemid 30395299)
    • (2000) Pharmaceutical Research , vol.17 , Issue.4 , pp. 439-444
    • Lobenberg, R.1    Kramer, J.2    Shah, V.P.3    Amidon, G.L.4    Dressman, J.B.5
  • 45
    • 0033805179 scopus 로고    scopus 로고
    • In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs
    • Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11(Suppl 2):S73-80
    • (2000) Eur J Pharm Sci , vol.11 , Issue.SUPPL. 2
    • Dressman, J.B.1    Reppas, C.2
  • 46
    • 78649714856 scopus 로고    scopus 로고
    • Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF dissolution technologies
    • Kloefer B, Van Hoogevest P, Moloney R, et al. Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF dissolution technologies. Dissol Technol 2010;17:6-13
    • (2010) Dissol Technol , vol.17 , pp. 6-13
    • Kloefer, B.1    Van Hoogevest, P.2    Moloney, R.3
  • 47
    • 79957861493 scopus 로고    scopus 로고
    • Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology
    • Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427-40
    • (2011) Adv Drug Deliv Rev , vol.63 , pp. 427-40
    • Merisko-Liversidge, E.1    Liversidge, G.G.2
  • 48
    • 79551516513 scopus 로고    scopus 로고
    • Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles
    • Juenemann D, Jantratid E, Wagner C, et al. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm 2011;77:257-64
    • (2011) Eur J Pharm Biopharm , vol.77 , pp. 257-64
    • Juenemann, D.1    Jantratid, E.2    Wagner, C.3
  • 49
    • 0028824401 scopus 로고
    • Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
    • Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309-13
    • (1995) Int J Pharm , vol.125 , pp. 309-13
    • Liversidge, G.G.1    Conzentino, P.2
  • 50
    • 77955656443 scopus 로고    scopus 로고
    • Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans
    • Shono Y, Jantratid E, Kesisoglou F, et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010;76:95-104
    • (2010) Eur J Pharm Biopharm , vol.76 , pp. 95-104
    • Shono, Y.1    Jantratid, E.2    Kesisoglou, F.3
  • 53
    • 33750089277 scopus 로고    scopus 로고
    • Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base
    • DOI 10.1016/j.ejpb.2006.05.008, PII S0939641106001408
    • Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb- 35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006;64:360-8 (Pubitemid 44585201)
    • (2006) European Journal of Pharmaceutics and Biopharmaceutics , vol.64 , Issue.3 , pp. 360-368
    • Hecq, J.1    Deleers, M.2    Fanara, D.3    Vranckx, H.4    Boulanger, P.5    Le Lamer, S.6    Amighi, K.7
  • 54
    • 80054816280 scopus 로고    scopus 로고
    • Salt screening and selection: New challenges and considerations in the modern pharmaceutical research and development paradigm
    • Qiu Y Chen Y Zhang GGZ Liu L Porter WR. Editors Academic Press, Burlington, London, San Diego, New York
    • Tong WT. Salt screening and selection: new challenges and considerations in the modern pharmaceutical research and development paradigm In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR. editors. Developing Oral Dosage Forms: pharmaceutical theory and practice. Academic Press; Burlington, London, San Diego, New York; 2009. p. 75-85
    • (2009) Developing Oral Dosage Forms: Pharmaceutical Theory and Practice , pp. 75-85
    • Tong, W.T.1
  • 55
    • 77956879551 scopus 로고    scopus 로고
    • High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate
    • Kojima T, Tsutsumi S, Yamamoto K, et al. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int J Pharm 2010;399:52-9
    • (2010) Int J Pharm , vol.399 , pp. 52-9
    • Kojima, T.1    Tsutsumi, S.2    Yamamoto, K.3
  • 57
    • 0030031766 scopus 로고    scopus 로고
    • Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
    • Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4
    • (1996) Cancer Res , vol.56 , pp. 100-4
    • Buchdunger, E.1    Zimmermann, J.2    Mett, H.3
  • 62
    • 70350776969 scopus 로고    scopus 로고
    • Nanoparticle Albumin-Bound (NAB) technology is a promising method for anti-cancer drug delivery
    • Fu Q, Sun J, Zhang W, et al. Nanoparticle Albumin-Bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anticancer Drug Discov 2009;4:262-72
    • (2009) Recent Patents Anticancer Drug Discov , vol.4 , pp. 262-72
    • Fu, Q.1    Sun, J.2    Zhang, W.3
  • 65
    • 77957255549 scopus 로고    scopus 로고
    • Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach chemical engineering & technology
    • Juhnke M, Berghausen J, Timpe C. Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach chemical engineering & technology. Chem Eng Technol 2010;33:1412-18
    • (2010) Chem Eng Technol , vol.33 , pp. 1412-18
    • Juhnke, M.1    Berghausen, J.2    Timpe, C.3
  • 66
    • 78649737917 scopus 로고    scopus 로고
    • Nano-suspension technology: A review
    • Lakshmi P, Kumar GH. Nano-suspension technology: a review. Int J Pharm Pharm 2010;2:35-40
    • (2010) Int J Pharm Pharm , vol.2 , pp. 35-40
    • Lakshmi, P.1    Kumar, G.H.2
  • 67
    • 34548134519 scopus 로고    scopus 로고
    • Cyclodextrins as pharmaceutical solubilizers
    • DOI 10.1016/j.addr.2007.05.012, PII S0169409X07000841
    • Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66 (Pubitemid 47299263)
    • (2007) Advanced Drug Delivery Reviews , vol.59 , Issue.7 , pp. 645-666
    • Brewster, M.E.1    Loftsson, T.2
  • 68
    • 84857658288 scopus 로고    scopus 로고
    • Cydex Pharmaceuticals. Inc
    • Cydex Pharmaceuticals, Inc.: Marketed products. Available from: http://cydexpharma.com/approvedproducts.html
    • Marketed Products
  • 75
    • 77955468413 scopus 로고    scopus 로고
    • Phospholipids and lipid-based formulations in oral drug delivery
    • Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010;27:1469-86
    • (2010) Pharm Res , vol.27 , pp. 1469-86
    • Fricker, G.1    Kromp, T.2    Wendel, A.3
  • 76
    • 78049499869 scopus 로고    scopus 로고
    • New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs
    • Mullertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010; In press
    • (2010) J Pharm Pharmacol
    • Mullertz, A.1    Ogbonna, A.2    Ren, S.3
  • 77
    • 79952224749 scopus 로고    scopus 로고
    • Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects
    • Kuentz M. Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects. J Drug Deliv Sci Technol 2011;21:17-20
    • (2011) J Drug Deliv Sci Technol , vol.21 , pp. 17-20
    • Kuentz, M.1
  • 78
    • 80054799364 scopus 로고    scopus 로고
    • A review : self emulsifying drug delivery system
    • Mistry RB, Sheth NS. A review : self emulsifying drug delivery system. Int J Pharm Pharm Sci 2011;3:23-8
    • (2011) Int J Pharm Pharm Sci , vol.3 , pp. 23-8
    • Mistry, R.B.1    Sheth, N.S.2
  • 79
    • 10444279209 scopus 로고    scopus 로고
    • Cyclodextrin-based pharmaceutics: Past, present and future
    • DOI 10.1038/nrd1576
    • Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35 (Pubitemid 39642365)
    • (2004) Nature Reviews Drug Discovery , vol.3 , Issue.12 , pp. 1023-1035
    • Davis, M.E.1    Brewster, M.E.2
  • 80
    • 21844459973 scopus 로고    scopus 로고
    • 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review
    • DOI 10.1016/j.fct.2005.03.007, PII S0278691505001006
    • Gould S, Scott RC. 2-Hydroxypropylbeta- cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43:1451-9 (Pubitemid 40961909)
    • (2005) Food and Chemical Toxicology , vol.43 , Issue.10 , pp. 1451-1459
    • Gould, S.1    Scott, R.C.2
  • 81
    • 85015640989 scopus 로고    scopus 로고
    • Melt-Extruded Molecular Dispersions
    • Ghebre Sellassie I Martin C. editors Marcel Dekker, New York
    • Breitenbach J, Magerlein M. Melt-Extruded Molecular Dispersions. In: Ghebre Sellassie I, Martin C. editors. Pharmaceutical extrusion technology. Marcel Dekker; New York, 2003. p. 245-60
    • (2003) Pharmaceutical Extrusion Technology , pp. 245-60
    • Breitenbach, J.1    Magerlein, M.2
  • 82
    • 0015124656 scopus 로고
    • Pharmaceutical applications of solid dispersion systems
    • Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302
    • (1971) J Pharm Sci , vol.60 , pp. 1281-302
    • Chiou, W.L.1    Riegelman, S.2
  • 83
    • 34447296485 scopus 로고    scopus 로고
    • Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends
    • DOI 10.1208/pt0802027, 50
    • Prodduturi S, Urman KL, Otaigbe JU, et al. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech 2007;8:E1-10 (Pubitemid 47053749)
    • (2007) AAPS PharmSciTech , vol.8 , Issue.2
    • Prodduturi, S.1    Urman, K.L.2    Otaigbe, J.U.3    Repka, M.A.4
  • 84
    • 75749094421 scopus 로고    scopus 로고
    • Review: Physical chemistry of solid dispersions
    • Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61:1571-86
    • (2009) J Pharm Pharmacol , vol.61 , pp. 1571-86
    • Janssens, S.1    Van Den Mooter, G.2
  • 85
    • 84857648607 scopus 로고    scopus 로고
    • Sporanox product. Available from: http://www.rxlist.com/sporanox-drug.htm
    • Sporanox Product
  • 86
    • 84857656148 scopus 로고    scopus 로고
    • Intelence product. Available from: http://www.rxlist.com/intelence-drug. htm
    • Intelence Product
  • 87
    • 84857652797 scopus 로고    scopus 로고
    • Prograf product. Available from: http://www.rxlist.com/prograf-drug.htm
    • Prograf Product
  • 88
    • 84857644437 scopus 로고    scopus 로고
    • Crestor product. Available from: http://www.rxlist.com/crestor-drug.htm
    • Crestor Product
  • 89
    • 84857658825 scopus 로고    scopus 로고
    • Gris-PEG product. Available from: http://www.rxlist.com/gris-peg-drug.htm
    • Gris-PEG Product
  • 90
    • 0020471096 scopus 로고
    • Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG®) plain tablets
    • Aoyagi N, Ogata H, Kaniwa N, et al. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn 1982;5:120-4 (Pubitemid 12121224)
    • (1982) Journal of Pharmacobio-Dynamics , vol.5 , Issue.2 , pp. 120-124
    • Aoyagi, N.1    Ogata, H.2    Kaniwa, N.3    Ejima, A.4
  • 91
    • 84857646976 scopus 로고    scopus 로고
    • Kaletra product. Available from: http://www.rxlist.com/kaletra-tablets- drug.htm
    • Kaletra Product
  • 92
    • 84857656156 scopus 로고    scopus 로고
    • Rapamune product. Available from: http://www.rxlist.com/rapamune-drug.htm
    • Rapamune Product
  • 93
    • 84857652762 scopus 로고    scopus 로고
    • Emend oral product. Available from: http://www.rxlist.com/emend-drug.htm
    • Emend Oral Product
  • 95
    • 84857642902 scopus 로고    scopus 로고
    • Megace ES product. Available from: http://www.rxlist.com/megace-es-drug. htm
    • Megace ES Product
  • 96
    • 84857652002 scopus 로고    scopus 로고
    • Megace ES product UK. Available from: http://www.medicines.org.uk/EMC/ medicine/346/SPC/Megace+160+mg +Tablets/
    • Megace ES Product UK
  • 97
    • 77952497288 scopus 로고    scopus 로고
    • Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension
    • Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine 2009;4:185-92
    • (2009) Int J Nanomedicine , vol.4 , pp. 185-92
    • Deschamps, B.1    Musaji, N.2    Gillespie, J.A.3
  • 98
    • 66149129222 scopus 로고    scopus 로고
    • Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer
    • Miele E, Spinelli GP, Tomao F, et al. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009;4:99-105
    • (2009) Int J Nanomedicine , vol.4 , pp. 99-105
    • Miele, E.1    Spinelli, G.P.2    Tomao, F.3
  • 99
    • 30444457035 scopus 로고    scopus 로고
    • Case report: Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions
    • Micha JP, Goldstein BH, Birk CL, et al. Case report: Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437-43
    • (2006) Gynecol Oncol , vol.100 , pp. 437-43
    • Micha, J.P.1    Goldstein, B.H.2    Birk, C.L.3
  • 100
    • 84857652239 scopus 로고    scopus 로고
    • Abraxane product. Available from: http://www.rxlist.com/abraxane-drug.htm
    • Abraxane Product
  • 101
    • 84857641906 scopus 로고    scopus 로고
    • Albumin product. Available from: http://www.orgyn.com/resources/genrx/ D000114.asp
    • Albumin Product
  • 102
    • 84857658781 scopus 로고    scopus 로고
    • Invega sustenna product. Available from: http://www.rxlist.com/invega- sustennadrug.htm
    • Invega Sustenna Product
  • 103
  • 104
    • 1642397172 scopus 로고    scopus 로고
    • Lipid-based formulations of amphotericin B
    • DOI 10.1358/dot.2004.40.2.799425
    • Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004;40:133-45 (Pubitemid 38387618)
    • (2004) Drugs of Today , vol.40 , Issue.2 , pp. 133-145
    • Veerareddy, P.R.1    Vobalaboina, V.2
  • 105
    • 80054810389 scopus 로고    scopus 로고
    • EMA 2008
    • (2008) EMA
  • 106
    • 0003069473 scopus 로고
    • An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE)
    • Fidler IJ, Lopez-Berestein G. editors Alan R. Liss, Inc, New York
    • Van Hoogevest P, Fankhauser P. An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE). In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York 1989. p. 453
    • (1989) Liposomes in the Therapy of Infectious Diseases and Cancer , pp. 453
    • Van Hoogevest, P.1    Fankhauser, P.2
  • 107
    • 0021930709 scopus 로고
    • Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes
    • Schwartz RS, Tanaka Y, Fidler IJ, et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J Clin Invest 1985;75:1965-72 (Pubitemid 15233585)
    • (1985) Journal of Clinical Investigation , vol.75 , Issue.6 , pp. 1965-1972
    • Schwartz, R.S.1    Tanaka, Y.2    Fidler, I.J.3
  • 108
    • 0012694409 scopus 로고
    • Comparison of free and liposomal MTP-PE. Pharmacological and toxicological aspects
    • Fidler IJ Lopez-Berestein G. editors Alan R. Liss Inc; New York
    • Schumann G, van Hoogevest P, Fankhauser P, et al.Comparison of free and liposomal MTP-PE. Pharmacological and toxicological aspects. In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York; 1989. p. 191
    • (1989) Liposomes in the Therapy of Infectious Diseases and Cancer , pp. 191
    • Schumann, G.1    Van Hoogevest, P.2    Fankhauser, P.3
  • 110
  • 113
    • 0025707612 scopus 로고
    • Biodistribution of tritiated benzoporphyrin derivative (3HBPD- MA), a new potent photosensitizer, in normal and tumor-bearing mice
    • Richter AM, Cerruti-Sola S, Sternberg ED, et al. Biodistribution of tritiated benzoporphyrin derivative (3HBPD- MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990;5:231-44
    • (1990) J Photochem Photobiol B , vol.5 , pp. 231-44
    • Richter, A.M.1    Cerruti-Sola, S.2    Sternberg, E.D.3
  • 115
    • 84857645315 scopus 로고    scopus 로고
    • Definity product. Available from: http://www.rxlist.com/definity-drug.htm
    • Definity Product
  • 118
    • 80054824342 scopus 로고    scopus 로고
    • A FDA perspective on nanomedicine: Current initiatives in the US
    • Pena C. A FDA perspective on nanomedicine: current initiatives in the US. In: Commisioner Oot; 2010
    • (2010) Commisioner Oot
    • Pena, C.1
  • 119
    • 80054825577 scopus 로고    scopus 로고
    • Manual of policies and procedures MAPP5015.9. Reporting format in nanotechnology information in CMC review 6/3/2010
    • Manual of policies and procedures MAPP5015.9. Reporting format in nanotechnology information in CMC review 6/3/2010. In: Science CodearOop; 2010
    • (2010) Science CodearOop
  • 120
    • 79953251219 scopus 로고    scopus 로고
    • Self-assembly of cyclodextrins: The effect of the guest molecule
    • Messner M, Kurkov SV, Flavia-Piera R, et al. Self-assembly of cyclodextrins: the effect of the guest molecule. Int J Pharm 2011;408:235-47
    • (2011) Int J Pharm , vol.408 , pp. 235-47
    • Messner, M.1    Kurkov, S.V.2    Flavia-Piera, R.3
  • 121
    • 79952314729 scopus 로고    scopus 로고
    • Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes
    • Messner M, Kurkov SV, Brewster ME, et al. Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes. Int J Pharm 2011;407:174-83
    • (2011) Int J Pharm , vol.407 , pp. 174-83
    • Messner, M.1    Kurkov, S.V.2    Brewster, M.E.3
  • 122
    • 77951210910 scopus 로고    scopus 로고
    • Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation
    • Van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010 54: 2042-50
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 2042-2050
    • Van't Klooster, G.1    Hoeben, E.2    Borghys, H.3
  • 123
    • 0036181889 scopus 로고    scopus 로고
    • Practical aspects of lyophilization using non-aqueous co-solvent systems
    • DOI 10.1016/S0928-0987(01)00221-4, PII S0928098701002214
    • Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 2002;15:115-33 (Pubitemid 34155373)
    • (2002) European Journal of Pharmaceutical Sciences , vol.15 , Issue.2 , pp. 115-133
    • Teagarden, D.L.1    Baker, D.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.